Stock UNC UCB
Add to a list
To use this feature you must be a member
Log inSign up

Financials UCB Deutsche Boerse AG

Equities

UNC

BE0003739530

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 04:25:53 2024-04-26 am EDT 		5-day change 1st Jan Change
122.6 EUR +1.83% Intraday chart for UCB +3.68% +55.92%
Apr. 11 Berenberg Reiterates UCB's Purchase Rating, Raises PT MT
Apr. 11 UCB : Berenberg, Buy, raises its price target CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,355 15,962 18,947 13,973 14,969 23,633 - -
Enterprise Value (EV) 1 13,343 17,373 19,807 15,973 17,146 25,262 24,435 23,634
P/E ratio 16.8 x 21.8 x 17.9 x 33.4 x 43.6 x 50.8 x 25.8 x 19.3 x
Yield 1.75% 1.5% 1.3% 1.81% 1.72% 1.12% 1.17% 1.18%
Capitalization / Revenue 2.72 x 2.99 x 3.28 x 2.53 x 2.85 x 4.21 x 3.74 x 3.39 x
EV / Revenue 2.72 x 3.25 x 3.43 x 2.9 x 3.26 x 4.5 x 3.87 x 3.39 x
EV / EBITDA 9.32 x 12.1 x 12.1 x 12.7 x 12.7 x 18.3 x 12.8 x 10.5 x
EV / FCF 17 x 21.1 x 15.6 x 18.4 x 38.5 x 24.8 x 18.1 x 15.3 x
FCF Yield 5.87% 4.75% 6.42% 5.43% 2.6% 4.04% 5.52% 6.52%
Price to Book 1.9 x 2.2 x 2.32 x 1.58 x 1.67 x 2.55 x 2.38 x 2.16 x
Nbr of stocks (in thousands) 188,367 188,941 188,812 189,959 189,721 189,751 - -
Reference price 2 70.90 84.48 100.4 73.56 78.90 124.6 124.6 124.6
Announcement Date 2/20/20 2/25/21 2/24/22 2/22/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,913 5,347 5,777 5,517 5,252 5,615 6,314 6,966
EBITDA 1 1,431 1,441 1,641 1,260 1,349 1,381 1,913 2,258
EBIT 1 1,118 1,093 1,318 675 657 685.2 1,183 1,546
Operating Margin 22.76% 20.44% 22.81% 12.23% 12.51% 12.2% 18.73% 22.2%
Earnings before Tax (EBT) 1 960 880 1,226 511 441 560.6 1,079 1,404
Net income 1 792 732 1,058 418 343 466.2 880.2 1,128
Net margin 16.12% 13.69% 18.31% 7.58% 6.53% 8.3% 13.94% 16.2%
EPS 2 4.230 3.870 5.600 2.200 1.810 2.452 4.835 6.467
Free Cash Flow 1 783 825 1,271 867 445 1,019 1,349 1,542
FCF margin 15.94% 15.43% 22% 15.72% 8.47% 18.15% 21.36% 22.13%
FCF Conversion (EBITDA) 54.72% 57.25% 77.45% 68.81% 32.99% 73.83% 70.51% 68.28%
FCF Conversion (Net income) 98.86% 112.7% 120.13% 207.42% 129.74% 218.63% 153.22% 136.62%
Dividend per Share 2 1.240 1.270 1.300 1.330 1.360 1.398 1.455 1.472
Announcement Date 2/20/20 2/25/21 2/24/22 2/22/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 Q2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 2,590 2,608 2,739 2,778 2,999 - 2,925 2,592 2,589 2,663 2,605 3,005
EBITDA 707 783 658 843 798 - 814 446 801 548 - -
EBIT 1 547 614 479 682 636 234 551 124 486 171 199.6 483.6
Operating Margin 21.12% 23.54% 17.49% 24.55% 21.21% - 18.84% 4.78% 18.77% 6.42% 7.66% 16.09%
Earnings before Tax (EBT) 416 458 422 643 583 - 481 30 401 40 - -
Net income 381 363 369 571 487 - 399 19 311 32 - -
Net margin 14.71% 13.92% 13.47% 20.55% 16.24% - 13.64% 0.73% 12.01% 1.2% - -
EPS 2.030 1.920 1.950 3.020 2.580 - 2.100 0.1000 1.600 - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 2/20/20 7/27/20 2/25/21 7/29/21 2/24/22 7/28/22 7/28/22 2/22/23 7/27/23 2/28/24 - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 1,411 860 2,000 2,177 1,628 802 0.23
Net Cash position 1 12 - - - - - - -
Leverage (Debt/EBITDA) - 0.9792 x 0.5241 x 1.587 x 1.614 x 1.179 x 0.4191 x 0.000102 x
Free Cash Flow 1 783 825 1,271 867 445 1,019 1,349 1,542
ROE (net income / shareholders' equity) 14.6% 14.2% 15.7% 9.5% 8.83% 8.02% 12.1% 13.3%
ROA (Net income/ Total Assets) 7.34% 8.32% 8.91% 5.51% 5.07% 3.37% 5.05% 4.67%
Assets 1 10,798 8,798 11,878 7,583 6,767 13,833 17,419 24,141
Book Value Per Share 2 37.30 38.50 43.20 46.60 47.30 48.80 52.30 57.60
Cash Flow per Share 2 4.710 5.570 8.000 5.740 3.900 5.390 7.590 9.300
Capex 1 99 256 282 252 316 264 284 310
Capex / Sales 2.02% 4.79% 4.88% 4.57% 6.02% 4.7% 4.49% 4.46%
Announcement Date 2/20/20 2/25/21 2/24/22 2/22/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for UCB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
124.6 EUR
Average target price
123.2 EUR
Spread / Average Target
-1.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
+2.29% 7.72B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. UCB Stock
  4. UNC Stock
  5. Financials UCB